SemBioSys submits IND for safflower-produced insulin
This article was originally published in Scrip
SemBioSys Genetics has submitted an IND application to the US FDA for a safflower-produced recombinant human insulin, with a view to starting a Phase I/II trial in the fourth quarter.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.